Lv71
4985 积分 2021-02-02 加入
Reflections on Medicinal Chemistry at Merck, West Point
2小时前
待确认
Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause
30天前
已完结
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia
2个月前
已完结
Novel Imidazole Phenoxyacetic Acids as Inhibitors of USP30 for Neuroprotection Implication via the Ubiquitin-Rho-110 Fluorometric Assay: Design, Synthesis, and In Silico and Biochemical Assays
3个月前
已完结
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
3个月前
已完结
WCN24-2618 ENCHANCEMENT OF MITOPHAGY VIA USP30 INHIBITION AS A THERAPEUTIC STRATEGY FOR ACUTE KIDNEY INJURY
3个月前
已完结
MTX652, a Novel Selective USP30 Inhibitor for the Treatment of AKI: Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections
3个月前
已关闭
Development of novel pyrazole-1,2,4-triazole derivatives as tyrosinase inhibitors: Design, preparation, mechanism of action and anti-browning application
3个月前
已完结
Targeting the FGFR Pathway in Patients with Advanced Solid Tumors
3个月前
已完结
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause
3个月前
已完结
皖公网安备34019202002308
